Precision Diagnosis and Care for Families With Pulmonary Fibrosis in Ireland

Recruiting

• Conditions: Connective Tissue Diseases; Interstitial Lung Disease; Idiopathic Pulmonary Fibrosis; Familial Idiopathic Pulmonary Fibrosis; Pulmonary Fibrosis; Pulmonary Fibrosis Interstitial

• Registration Number: NCT06702228
• Lead Sponsor: Royal College of Surgeons, Ireland

Brief Summary

This study aims to improve the understanding of how genes and the environment can influence and cause pulmonary fibrosis. By identifying the presence of genes and other factors that can put people at risk of developing pulmonary fibrosis, the influence these factors have on the progression of the disease can be studied.

Interstitial lung disease (ILD) is the medical term given to a group of lung diseases affecting the same part of the lung, the interstitium, each with similar symptoms. In some of these diseases, inflammation leads to lung scarring, known as fibrosis. Idiopathic Pulmonary Fibrosis (IPF) is one of these diseases; it has a particular pattern on computed tomography (CT) scans. IPF is 'idiopathic' as it is not yet fully understood why it happens. It has a poor prognosis. The average survival time is three to five years after diagnosis. While new antifibrotic drugs offer hope of slowing disease progression, lung transplant is the only cure, and it comes with its significant risks.

Although it is not fully understood what causes IPF, it is known that genetic factors significantly increase the risk of developing the disease. Up to a quarter (25%) of people with IPF with a family history appear to have a causative genetic variant. Familial-pulmonary-fibrosis (FPF), the term for people with at least one relative with IPF, may have worse disease when compared to those without a family history. However, this needs more research. Patients with specific genes, telomere-related gene variants, appear to have a greater risk of developing blood disorders from medications given to suppress the body's immune system after a lung transplant.

Progressive pulmonary fibrosis is pulmonary fibrosis where there is irreversible worsening of the disease, worsening of lung function, respiratory symptoms and even early death. It is of growing importance regardless of the cause, whether it be idiopathic, familial or secondary to a connective tissue disease. ILD is increasingly recognised as a complication of connective tissue diseases. It is the leading cause of death in people with systemic sclerosis. The new antifibrotic drugs slow the progression of CTD-ILD. People with progressive pulmonary fibrosis who have a greater than 10% drop over one year in a measure of their lung function, called the forced vital capacity, benefit most from antifibrotic therapy. Early identification of people with progressive disease would allow the commencement of treatment quicker. At-home spirometry may be a way of identifying those who are worsening early.

This study hypothesises that by improving knowledge of factors that affect disease behaviour and progression and assessing tools for the early identification of progressive disease, such as at-home spirometry and CT scan pattern determination by deep-learning analysis, we can provide 'precision' diagnosis and treatment. It is hoped that this improved understanding will help reduce the clinical risk for people with pulmonary fibrosis and their families.

This study aims to recruit 300 patients: 100 with IPF, 100 with FPF, and 100 with CTD ILD. Each participant will be followed for one year.

This observational study aims to help answer a number of questions:

1. What genetic variants cause people to develop ILD, and which increase a person's risk of developing ILD are present in the study population?

2. How does pulmonary fibrosis behave in people who have a family history of IPF compared to those who do not and in people with CTD-ILD?

3. Are different types of pulmonary fibrosis more progressive than others i.e. Is pulmonary fibrosis in those with a family history of pulmonary fibrosis more progressive than in those who do not have a family history?

4. Is the disease in those with a genetic variant known to cause ILD worse than in those who don't have a gene?

5. Can at-home spirometry help identify people at risk of progressive disease early?

6. Can deep-learning analysis (AI) be used to find CT scan patterns to predict when pulmonary fibrosis will worsen?

Detailed Description

Not available

Study Timeline

• Study Start: 2021-09-28
• Status Verified: 2024-06
• Study First Submitted: 2024-06-06
• Study First Submitted QC: 2024-11-20
• Last Update Submitted: 2024-11-20
• Study First Posted: 2024-11-22
• Last Update Posted: 2024-11-22
• Primary Completion: 2026-07-01
• Study Completion: 2028-04-01

Recruitment & Eligibility

• Status: RECRUITING
• Sex: All
• Target Recruitment: 300

Inclusion Criteria

• Able and willing to give written informed consent.

• An MDT diagnosis of fibrotic ILD which fall into one of the following three catagories;

  1. Have a multidisciplinary team (MDT) diagnosis of a fibrotic interstitial lung disease, reporting one or more relatives with a fibrotic form of ILD
  2. Have a MDT diagnosis of IPF in accordance with consensus criteria, ATS, ERS, JRS, ALAT guidelines without a family history of pulmonary fibrosis.
  3. Meet the American College of Rheumatology/European League Against Rheumatism criteria for rheumatoid arthritis, scleroderma, Sjogren's syndrome, idiopathic inflammatory myopathy and systemic lupus erythematosus.

Exclusion Criteria

• Currently participating in an interventional clinic trial.
• Change in clinical phenotype from initial radiological diagnosis to screening.
• Acute or chronic hypersensitivity pneumonitis with consensus criteria (appropriate exposure history, radiological features ± avian and fungal precipitins).
• Asbestosis (appropriate occupational history and radiological evidence of asbestos exposure)
• Life expectancy for any disease, including ILD <12 months (investigator assessment)
• Major extrapulmonary physiological restriction (e.g. chest wall abnormality, large pleural effusion)

Study & Design

• Study Type: OBSERVATIONAL
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
Determine if familial-pulmonary-fibrosis is more progressive than sporadic-IPF	12-months of entering the study	Disease progression defined as relative FVC decline ≥10% or death/lung transplant within 12 months of entering the study.

Secondary Outcome Measures

Name	Time	Method
Identify radiological phenotypes linked to disease behavior in pulmonary fibrosis	12 months	Use of computational methods to identify novel radiologic phenotypes linked to disease behaviour
Changes and patterns in at home-spirometry with the patientMpower App	12 Months	Using the patientMpower App patients will take twice-weekly home spirometry readings which will be analysed for changes and patterns in spirometry readings
All-cause mortality	Time of censoring or 12 months
Identify genotypes present in our study population	Within first 6 months of study recruitment	Identify pathogenic genetic variants known to cause ILD present in our study population as well as at risk alleles e.g. MUC5B.
Change in quality of life scores from baseline to 1 year	From date of study entry (baseline) until 12-month-assessment questionnaire completed, 12 months	Identify the number of participants with a change in their quality of life (QOL) scores over a twelve month period and if the change in QOL score is more likely to be associated factors such as genotype. Quality of life will be assessed based on the results of quality of life questionnaires completed including the Medical Research Council Dyspnoea Scale, Leicester Cough Questionnaire, The King's Brief Interstitial Lung Disease and EQ-5D-5L. The CTD-ILD cohort will also have Patient Global Assessment and Clinician Global Assessment scores recorded. These will be completed as close as possible to 0 months for the baseline score and at 6 and 12 months to assess for a change.
Change in 6MWT from baseline to 1 year	On entry to study (baseline) to end of observation period (12 months)	6-Minute walk tests will be carried out in a clinical setting by a trained physiotherapist at baseline (0), 6 and 12 months.
Change in pulmonary function tests from baseline to 1 year	Baseline (0 months) to 12 month follow-up	Changes in forced vital capacity and diffusing capacity of the lungs for carbon monoxide will be assessed
Change in HRCT scan	12 months	Comparison between baseline CT Thorax and follow-up CT scan 1 year later using American Thoracic Society Guidelines to determine if there is radiological progression.

Trial Locations

Locations (1)

Beaumont Hospital; 🇮🇪 Dublin, Ireland